Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

$24.99

Current Ratio
since 2005

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Pfizer Inc., current ratio, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in millions


Current Assets
Current assets demonstrated fluctuations over the reported period. From 2005 to 2009, there was an overall increasing trend, starting at approximately 41.9 billion US dollars and peaking at about 61.7 billion US dollars. Post-2009, current assets generally stabilized with periodic decreases and increases, reaching a value of around 50.4 billion US dollars by 2024. Notably, there was a marked dip from 2014 to 2016, followed by recovery phases, and a slight decline again in the last two years.
Current Liabilities
Current liabilities showed a more variable pattern. Initially, liabilities declined from around 28.4 billion US dollars in 2005 to approximately 21.4 billion US dollars in 2006. Afterward, they increased with some volatility, reaching almost 42.7 billion US dollars in 2021, the highest point in the timespan. Subsequently, current liabilities decreased somewhat but remained elevated relative to the earlier years, ending at about 43.0 billion US dollars in 2024. The data indicates several periods of significant rises, especially in the years surrounding 2020 and 2021.
Current Ratio
The current ratio, reflecting liquidity, varied significantly throughout the period. Early years showed relatively high liquidity with the ratio mostly above 2.0 between 2006 and 2014, peaking near 2.67 in 2014. However, from 2014 onwards, the ratio generally declined, often fluctuating around or below 1.5, and at times falling below 1.0, notably in 2019 (0.88) and 2023 (0.91). This downward trend implies a decreasing cushion of current assets relative to current liabilities, indicating tighter liquidity conditions as time progressed.
Overall Insights
The financial data suggests that while current assets have experienced moderate growth with fluctuations, current liabilities have increased more significantly over time, particularly post-2015. Consequently, the liquidity ratio has weakened, with the current ratio decreasing from a comfortable level above 2.0 in the earlier years to levels closer to or below 1.0 in the latest years. This trend signals potential pressure on short-term financial flexibility. Periods of elevated liabilities coupled with reduced liquidity ratios may necessitate management attention to working capital management and short-term financial strategy.

Comparison to Competitors

Pfizer Inc., current ratio, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Pfizer Inc., current ratio, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)